[et_pb_section fb_built="1" specialty="on" _builder_version="4.9.3" _module_preset="default" custom_padding="0px|0px|0px|||"][et_pb_column type="3_4" specialty_columns="3" _builder_version="3.25" custom_padding="|||" custom_padding__hover="|||"][et_pb_row_inner _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet" custom_padding="28px|||||"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" hover_enabled="0" sticky_enabled="0"]
QUESTION
Activity A.6a
Read the article by Yoshida, T., Yamauchi, H. and Sun, G.F., 2004. Chronic health effects in people exposed to arsenic via the drinking water: dose–response relationships in review. Toxicology and applied pharmacology, 198(3), pp.243-252.
Please access via reading list below. [CAM617 Library Reading List] [CAM617 Library Text List]
Refer to enHealth Guidelines as a reference and guide
Briefly summarise the information from the study by Yoshida et al., (2004) into the following five sections:
Issue Identification
Hazard Identification
Dose-Response Assessment
Exposure Assessment
Risk Characterisation
[/et_pb_text][et_pb_text _builder_version="4.9.3" _module_preset="default" width_tablet="" width_phone="100%" width_last_edited="on|phone" max_width="100%"]
| Subject |
Article Analysis |
Pages |
3 |
Style |
APA |
[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner module_class="the_answer" _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" width="100%" custom_margin="||||false|false" custom_margin_tablet="|0px|||false|false" custom_margin_phone="" custom_margin_last_edited="on|desktop"]
Answer
-
Article Summary: Yoshida et al., (2004)
Issue Identification
The identified issue in the article is poisoning that is caused by chronic arsenic which has become worldwide public health. Arsenic poisoning is a medical condition that happens when there is high level of arsenic in the body. According to the article, cases of human exposure occur from consumption of drinking water that has high amounts of inorganic arsenic.
Hazard Identification
The hazard identified in this case is arsenic, a naturally occurring component on earth’s crust and distributed throughout the environment in water, air, and land. This component is highly toxic when it its inorganic form. When consumed by humans mainly through water and its level becomes high in the body, , a process kwon as arsenic poisoning. Arsenic poisoning presents with symptoms such as swollen or red skin, abdominal pain, nausea and vomiting.
Dose-Response Assessment
In order to present with symptoms such as swollen or red skin, abdominal pain, nausea and vomiting, there must be high level of arsenic in the air, water or land. In this particular case, the arsenic must be in its inorganic form and concentrated in water, which is the main means through it affects people.
Exposure Assessment
Exposure assessment of the agent which is arsenic was conducted based on two major factors. The first one is its concentration on drinking water. According to the article, higher concentration of arsenic in water, the higher the likelihood that it will affect a larger number of people.
Risk Characterization
Risk characterization is based on the quality of the water people consume. While the paper acknowledges that arsenic is present in land, air, and water, water is the main channel through which it poisons people.
.
References
Yoshida, T., Yamauchi, H., & Sun, G. F. (2004). Chronic health effects in people exposed to arsenic via the drinking water: dose–response relationships in review. Toxicology and applied pharmacology, 198(3), 243-252.
[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|desktop" custom_padding="60px||6px|||"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" min_height="34px" custom_margin="||4px|1px||"]
Related Samples
[/et_pb_text][et_pb_divider color="#E02B20" divider_weight="2px" _builder_version="4.9.3" _module_preset="default" width="10%" module_alignment="center" custom_margin="|||349px||"][/et_pb_divider][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner use_custom_gutter="on" _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px||" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet" custom_padding="13px||16px|0px|false|false"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_blog fullwidth="off" post_type="project" posts_number="5" excerpt_length="26" show_more="on" show_pagination="off" _builder_version="4.9.3" _module_preset="default" header_font="|600|||||||" read_more_font="|600|||||||" read_more_text_color="#e02b20" width="100%" custom_padding="|||0px|false|false" border_radii="on|5px|5px|5px|5px" border_width_all="2px" box_shadow_style="preset1"][/et_pb_blog][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column type="1_4" _builder_version="3.25" custom_padding="|||" custom_padding__hover="|||"][et_pb_sidebar orientation="right" area="sidebar-1" _builder_version="4.9.3" _module_preset="default" custom_margin="|-3px||||"][/et_pb_sidebar][/et_pb_column][/et_pb_section]